Moderna's (MRNA) COVID-19 Vaccine Manufactured in Korea by Samsung Granted Marketing Authorization from Ministry of Food and Drug Safety of Korea

Moderna (MRNA) and Australia Collaborate to Bring mRNA Manufacturing to Australia

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia including access to Modernas mRNA development engine. The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Modernas vaccines in development for respiratory viruses. Moderna and the Australian government are committed to finalize the... More

Popular stocks with increasing volume: T LCID MRNA PTON EWT HOG

Popular stocks with increasing volume: T LCID MRNA PTON EWT HOG

Popular stocks with increasing volume: LCID MRNA PTON EWT HOG ATOS NAT EWJ

Popular stocks with increasing volume: LCID MRNA PTON EWT HOG ATOS NAT EWJ

Moderna (MRNA) Stock Gains While Street Analysts Discuss What Comes Next Following Early Flu Vaccine Data

Analysts continue to discuss early data for Modernas (NASDAQ: MRNA) flu vaccine, released by the company last week.

Morgan Stanley analyst Matthew Harrison described the early flu vaccine data as undifferentiated on Friday.

We believe the market was looking for data which supported clearly better efficacy, such that today's results are likely to pressure MRNA, the analyst said in a client note Friday.

In a follow-up note released today, Harrison discusses the next catalysts for Moderna going forward. The analyst rates MRNA shares as Equal Weight with a $313.00 per share price... More

Moderna (MRNA) Continues to Grind off Lows, Remains Down 5.5%

Moderna (NASDAQ: MRNA) continues to grind off lows, shares remain down 5.5%. A U.K. study that boosters give 70-75% Omicron protection is helping.

Boosters give 70-75% Omicron protection, U.K. study shows - Bloomberg

Boosters give 70-75% Omicron protection, U.K. study shows - Bloomberg

Moderna (MRNA) Stock Down 11% on Likely Disappointing Flu Vaccine Data, Seen as 'Undifferentiated' by Morgan Stanley

Morgan Stanley analyst Matthew Harrison briefly weighed in on the preliminary flu vaccine data released by Moderna (NASDAQ: MRNA) this morning.

Modernas mRNA-1010 vaccine candidate successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults, the company said in a press... More

Moderna (MRNA) opens down 12% as flu data called 'undifferentiated'

Moderna (NASDAQ: MRNA) opens down 12% as flu data called 'undifferentiated'.

Pre-Open Stock Movers 12/10: (CNTX) (AI) (ORCL) Higher; (ANGN) (CCNC) (MRNA) Lower (more...)

Pre-Open Stock Movers

Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) 22.6% LOWER; announced results from the exploratory phase-II GUARD trial of Angions ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data, based on the signal demonstrated in the clinically-relevant MAKE90 secondary endpoint.

Context Therapeutics Inc. (Nasdaq:... More

Moderna (MRNA) to Supply an 20M Doses of COVID-19 Vaccine to COVAX for 2021

Moderna (Nasdaq: MRNA) announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million doses to COVAX by December 31, 2021 for a total of 54 million doses made available to COVAX in 2021. Deliveries to COVAX Advance Market Commitment (AMC) countries have already begun.

These doses are included in Modernas previously announced agreement with Gavi and were originally scheduled for delivery in the first quarter of 2022. Given the acceleration into 2021, Moderna expects to supply up to 96.5 million doses in the first quarter of 2022 and an... More

Moderna (MRNA) flu vaccine data called 'undifferentiated' at Morgan Stanley

Analyst at Morgan Stanley weighed in Moderna (NASDAQ: MRNA) RNA-based experimental seasonal flu vaccine and called it undifferentiated versus Fluzone HD.

The analyst commented, "On A strains, mRNA-1010 achieved a ~6x increase in titers, similar for Fluzone HD. In B titers,... More

Moderna asks investors to wait for full data on flu vaccine amid selloff

By Leroy Leo and Mrinalika Roy

(Reuters) -Moderna Inc executives called on investors to wait for more data amid a sharp selloff in its shares on Friday, after early data showed its mRNA-based flu vaccine was no better than already approved shots in the market.

The company's shares tumbled 10% after its investor presentation showed antibody levels of its vaccine against all four strains of the influenza virus in an early-stage study were not as robust in older people as Sanofi's Fluzone HD.... More

Moderna (MRNA) Declines 7% Pre-Open Following Interim Phase 1 Data for mRNA Flu Vaccine and Program Update

Moderna (NASDAQ: MRNA) Declines 7% Pre-Open Following Interim Phase 1 Data for mRNA Flu Vaccine and Program Update

Moderna (MRNA) Reports Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first positive interim data from the Phase 1 study of the Companys quadrivalent seasonal flu vaccine candidate, mRNA-1010. In the study, mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers... More